News - Zytiga, Takeda Pharmaceuticals

Filter

Popular Filters

1 to 25 of 227 results

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

Seattle Genetics earns $6 million milestone under Adcetris accord with Takeda

08-04-2014

US biotech firm Seattle Genetics says it will receive milestone payments from Japan’s Takeda Pharmaceutical…

AdcetrisAsia-PacificBiotechnologyFinancialMarkets & MarketingOncologySeattle GeneticsSouth AmericaTakeda Pharmaceuticals

Mersana in deal with Takeda to develop ADCs

Mersana in deal with Takeda to develop ADCs

07-04-2014

Privately-held US biotech firm Mersana Therapeutics has entered into a collaboration agreement with Japanese…

Antibody-drug conjugateBiotechnologyBusiness FinanceHealth Medical PharmaHealth Medical PharmaLicensingMajorMersana TherapeuticsMillennium PharmaceuticalsOncologyResearchTakeda Pharmaceuticals

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Takeda gets positive CHMP opinion for Entyvio for UC and Crohn’s disease

21-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, today received a positive opinion form the European…

EntyvioEuropeGastro-intestinalsPharmaceuticalRegulationTakeda Pharmaceuticals

Report: New drugs needed for prostate cancer as incidents rise

Report: New drugs needed for prostate cancer as incidents rise

21-03-2014

Over half a million cases of prostate cancer will be diagnosed worldwide in 2014 leading to a demand…

EuropeJohnson & JohnsonOncologyPharmaceuticalResearchUSAXtandiZytiga

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan

09-03-2014

Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Actavis challenges Multaq and Colcrys patents

02-03-2014

Ireland-headquartered generic drugmaker Actavis revealed on Friday (February 28) that French pharma giant…

ActavisAnti-Arthritics/RheumaticsCardio-vascularColcrysGenericsLegalMultaqNorth AmericaPatents & Trade marksRegulationSanofiTakeda PharmaceuticalsUSA

Takeda’s new diabetes drug Vipidia debuts in UK

26-02-2014

Japan’s largest drugmaker Takeda Pharmaceuticals this morning launched its new type 2 diabetes drug…

alogliptinDiabetesMarkets & MarketingNorthern EuropePharmaceuticalTakeda PharmaceuticalsUKVipidia

Takeda re-aligns marketing system in Japan

24-02-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it decided to re-align its marketing system in…

Asia-PacificJapanManagementMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

Lundbeck’s Brintellex available in US pharmacies for depression

Lundbeck’s Brintellex available in US pharmacies for depression

22-01-2014

Lundbeck (LUN: CO) and Takeda Pharmaceutical (TYO: 4502) jointly announced today that Brintellix (vortioxetine)…

BrintellixLundbeckMarkets & MarketingNeurologicalPharmaceuticalRegulationTakeda PharmaceuticalsUSA

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Promising late-stage GI drugs could stabilize global market decline; report

16-01-2014

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis…

BiosimilarsGastro-intestinalsGlobalMarkets & MarketingPharmaceuticalRemicadeTakeda Pharmaceuticalsvedolizumab

Takeda appointments former GSK exec as head if CNS research

Takeda appointments former GSK exec as head if CNS research

15-01-2014

Takeda Pharmaceutical, Japan’s largest drug company, has appointed Emiliangelo Ratti as head of its…

BoardroomManagementPharmaceuticalTakeda Pharmaceuticals

Takeda to sell BIKEN varicella vaccine in Japan

Takeda to sell BIKEN varicella vaccine in Japan

15-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has reached agreement with the Research Foundation…

Asia-PacificMarkets & MarketingPharmaceuticalTakeda PharmaceuticalsVaccines

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

Takeda's vedolizumab enters Ph III in Japan for UC and Crohn's disease

08-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical revealed today that vedolizumab), an investigational…

Asia-PacificGastro-intestinalsPharmaceuticalResearchTakeda Pharmaceuticalsvedolizumab

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

Takeda stops development of diabetes candidate fasiglifam; PDUFA date for vedolizumab extended

27-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has decided voluntarily to terminate the development…

DiabetesfasiglifamGastro-intestinalsNorth AmericaPharmaceuticalRegulationResearchTakeda PharmaceuticalsUSAvedolizumab

Takeda collaboration with Medicines for Malaria Venture

Takeda collaboration with Medicines for Malaria Venture

26-12-2013

Japan’s largest drugmaker Takeda Pharmaceutical has entered into agreements with Medicines for Malaria…

DSM265ELQ300PharmaceuticalResearchTakeda PharmaceuticalsTropical diseases

Takeda sets sights on Israeli pharma market, with new subsidiary

Takeda sets sights on Israeli pharma market, with new subsidiary

18-12-2013

Through a European subsidiary, Japan’s largest drugmaker Takeda Pharmaceuticals today announced further…

ManagementMarkets & MarketingPharmaceuticalRest of the WorldTakeda Pharmaceuticals

Modest growth seen for MAbs market for colorectal cancer, as late-stage pipeline is weak

14-12-2013

The market value for monoclonal antibodies in colorectal cancer treatment will experience a moderate…

AvastinBiotechnologyBristol-Myers SquibbErbituxMarkets & MarketingMerck KGaAOncologyResearchRocheTakeda PharmaceuticalsVectibix

FDA advisory panel backs approval of Takeda’s vedolizumab

FDA advisory panel backs approval of Takeda’s vedolizumab

10-12-2013

A US Food and Drug Administration advisory committee has recommended approval of vedolizumab from Japan’s…

Gastro-intestinalsPharmaceuticalRegulationTakeda PharmaceuticalsUSAvedolizumab

1 to 25 of 227 results

Back to top